CEBPB and neoplasm: We also showed that the allele status of the germline variant rs4294451, located within the E9 region, can affect CEBPB-driven DPYD expression and sensitivity/resistance to 5-FU, making it a strong candidate biomarker for 5-FU toxicity risk and potentially tumor resistance to 5-FU–based cancer therapy.